ACADIA Pharmaceuticals, Inc.
| Nasdaq: ACAD
ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is developing a portfolio consisting of four advanced product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson's disease psychosis. It also has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma. ACADIA Pharmaceuticals was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.